Status:
COMPLETED
Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Bayer
Conditions:
Colorectal Liver Metastases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
1. Primovist-enhanced Magnetic resonance imaging (MRI) and Diffusion Weighted MRI (DW-MRI) is superior to Multidetector Computed axial Tomography (MDCT) in the detection of colorectal liver metastases...
Eligibility Criteria
Inclusion
- Patients with colorectal liver metastases already treated by chemotherapy and scheduled for surgical resection
- Patients with colorectal liver metastases scheduled to receive chemotherapy with possibility of future liver resection.
Exclusion
- Acute or Chronic Renal Disease with Estimated GFR (eGFR) \<30 mL/min.
- Hypersensitivity to MRI contrast or CT contrast or to any ingredient in the formulation or component of the container.
- Patients with: acute or chronic severe renal impairment (glomerular filtration rate \<30 mL/min/1.73 m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
- General contraindications to MRI such as pacemaker or ferromagnetic implants.
- Severe cardiovascular problems
- Pregnant or nursing women
- Age \<18 years
- Liver Surgery is not a possibility.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01255007
Start Date
September 1 2010
End Date
December 1 2014
Last Update
January 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2L7